HK1181760A1 - 氮雜環化合物 - Google Patents

氮雜環化合物

Info

Publication number
HK1181760A1
HK1181760A1 HK13108984.6A HK13108984A HK1181760A1 HK 1181760 A1 HK1181760 A1 HK 1181760A1 HK 13108984 A HK13108984 A HK 13108984A HK 1181760 A1 HK1181760 A1 HK 1181760A1
Authority
HK
Hong Kong
Prior art keywords
azacyclic compounds
azacyclic
compounds
Prior art date
Application number
HK13108984.6A
Other languages
English (en)
Inventor
讓．阿克曼
奧理莉亞．康特
丹尼爾．洪齊格
維爾納．奈德哈特
馬蒂亞斯．內特科文
坦賈．舒爾茲-加施
斯坦利．韋爾泰梅
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1181760A1 publication Critical patent/HK1181760A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HK13108984.6A 2010-08-13 2013-08-01 氮雜環化合物 HK1181760A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10172747 2010-08-13
PCT/EP2011/063727 WO2012020035A1 (en) 2010-08-13 2011-08-10 New azacyclic compounds

Publications (1)

Publication Number Publication Date
HK1181760A1 true HK1181760A1 (zh) 2013-11-15

Family

ID=44509322

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13108984.6A HK1181760A1 (zh) 2010-08-13 2013-08-01 氮雜環化合物

Country Status (12)

Country Link
US (3) US8552024B2 (zh)
EP (1) EP2603510A1 (zh)
JP (1) JP5886289B2 (zh)
KR (1) KR20130139871A (zh)
CN (1) CN103068826B (zh)
AR (1) AR082631A1 (zh)
CA (1) CA2806159A1 (zh)
HK (1) HK1181760A1 (zh)
MX (1) MX2013001762A (zh)
RU (1) RU2606513C2 (zh)
TW (1) TW201213328A (zh)
WO (1) WO2012020035A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097634B2 (en) * 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
US8552024B2 (en) * 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
HUE049982T2 (hu) 2014-11-14 2020-11-30 Hoffmann La Roche TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN109400608B (zh) * 2018-12-15 2021-08-31 西南大学 二氮杂螺[4，5]癸烷酒石酸类衍生物制备和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001261679A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
KR100783836B1 (ko) * 2004-01-08 2007-12-10 에프. 호프만-라 로슈 아게 글라이신 트랜스포터 1 및 글라이신 트랜스포터 2의억제제로서의 다이아자-스피로피페리딘 유도체
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
GEP20125565B (en) * 2004-11-10 2012-07-10 Incyte Corp Lactam compounds and their pharmaceutical use
TW200804382A (en) 2005-12-05 2008-01-16 Incyte Corp Lactam compounds and methods of using the same
CN101336243A (zh) * 2005-12-05 2008-12-31 因塞特公司 内酰胺化合物和其使用方法
US8026365B2 (en) * 2007-05-25 2011-09-27 Hoffman-La Roche Inc. 4,4-disubstituted piperidine derivatives
WO2009097997A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US8329904B2 (en) * 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US8389539B2 (en) * 2009-12-01 2013-03-05 Hoffman-La Roche Inc. Azacyclic derivatives
US8097634B2 (en) * 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
US8552024B2 (en) * 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds

Also Published As

Publication number Publication date
KR20130139871A (ko) 2013-12-23
MX2013001762A (es) 2013-03-18
JP5886289B2 (ja) 2016-03-16
CN103068826B (zh) 2016-08-31
EP2603510A1 (en) 2013-06-19
US20120041013A1 (en) 2012-02-16
US20140005400A1 (en) 2014-01-02
RU2013108748A (ru) 2014-09-20
CN103068826A (zh) 2013-04-24
TW201213328A (en) 2012-04-01
JP2013535510A (ja) 2013-09-12
CA2806159A1 (en) 2012-02-16
WO2012020035A1 (en) 2012-02-16
RU2606513C2 (ru) 2017-01-10
US20150148363A1 (en) 2015-05-28
AR082631A1 (es) 2012-12-19
US8552024B2 (en) 2013-10-08

Similar Documents

Publication Publication Date Title
HRP20181788T1 (hr) Supstituirani spojevi piridinon-piridinil
IL223783A0 (en) Pro-neurogenic compounds
GB201015949D0 (en) Compounds
GB201008134D0 (en) Compounds
HK1187908A1 (zh) 咪唑並三嗪酮化合物
EP2605658A4 (en) SPIROXAZOLIDINONVERBINDUNGEN
GB201007347D0 (en) Compounds
EP2649050A4 (en) LINKS
GB201002563D0 (en) Compounds
HK1181760A1 (zh) 氮雜環化合物
GB201008209D0 (en) Compounds
GB201001688D0 (en) Compounds
GB201002216D0 (en) Compounds
GB201015537D0 (en) Compounds
GB201008210D0 (en) Compounds
GB201001796D0 (en) Compounds
GB201021494D0 (en) Compounds
GB201022042D0 (en) Compounds
GB201019227D0 (en) Compounds
GB201015757D0 (en) Compounds
GB201015145D0 (en) Compounds
GB201014392D0 (en) Compounds
GB201014052D0 (en) Compounds
GB201013508D0 (en) Compounds
GB201013507D0 (en) Compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200806